Pancragen Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is Pancragen?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Pancreatic cell differentiation, glucose metabolism, epigenetic gene regulation, cellular aging, diabetic vascular complications
• First Investigated: Early 2000s; derived from peptides isolated from bovine pancreatic tissue
• Molecular Weight: 576.25 g/mol
• Amino Acid Sequence: Lys-Glu-Asp-Trp (KEDW)
• Research Status: Over 20 years of preclinical and limited observational research; no controlled Phase II or III human clinical trials
• Key Mechanisms: Proposed epigenetic regulation via DNA and histone interaction; transcription factor upregulation; anti-apoptotic signaling; glucose-insulin pathway modulation
• Published Studies: Primarily from the St. Petersburg Institute of Bioregulation and Gerontology; multiple peer-reviewed publications in Russian and international journals
• Clinical Trial Status: No registered controlled clinical trials; small observational studies in elderly subjects only
• Regulatory Classification: Research use only; not approved for human therapeutic, veterinary, or diagnostic applications

What is Pancragen?

Pancragen is a synthetic tetrapeptide bioregulator with the amino acid sequence Lysine-Glutamic Acid-Aspartic Acid-Tryptophan, abbreviated as KEDW. The compound belongs to a class of short-chain peptides called peptide bioregulators, a category developed through decades of research examining organ-specific regulatory peptides derived from animal tissues.

The peptide originated from work by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Khavinson’s laboratory has spent more than three decades investigating the hypothesis that short peptides extracted from specific organ tissues carry regulatory information that can modulate gene expression in corresponding organs of the same type. Pancragen represents the pancreas-targeting member of this broader family of short peptide bioregulators, each associated with a particular tissue.

The original research approach involved isolating peptide fractions from bovine pancreatic tissue, then identifying and synthesizing the shortest active sequences capable of reproducing the observed biological effects. The four-amino acid KEDW sequence emerged from this process as the minimal active unit hypothesized to carry pancreatic regulatory activity. Unlike most research peptides that bind to cell surface receptors and trigger downstream signaling cascades, Pancragen is proposed to enter cells directly and interact with nuclear components, including DNA and histone proteins.

Research interest centers on two connected areas. The first is pancreatic cell biology: whether the peptide can influence differentiation of pancreatic cell types and restore gene expression patterns that decline with aging. The second is metabolic function: whether changes in pancreatic cell biology translate into improved glucose handling and insulin dynamics, particularly in aged research models. Non-human primate studies using aged rhesus monkeys represent the most advanced preclinical model used to date, with some small observational studies conducted in elderly human subjects.

Pancragen is classified strictly as a research compound. It carries no approved therapeutic indication in any jurisdiction and is not intended for human consumption, clinical use, or veterinary application.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

Pancragen’s four-residue structure combines three charged amino acids with one aromatic residue. Lysine carries a positive charge at physiological pH. Glutamic acid and aspartic acid both carry negative charges. Tryptophan contributes an indole aromatic ring system, the largest and most structurally complex side chain among the standard amino acids.

Researchers hypothesize that this combination of charges and the aromatic ring system contributes to the peptide’s proposed ability to penetrate cellular membranes and reach nuclear compartments. The molecular weight of 576 Da places Pancragen well below the threshold typically associated with passive membrane permeability, which may facilitate cellular uptake without requiring active transport mechanisms.

The compact four-residue structure differs substantially from longer research peptides. This brevity means the molecule carries fewer potential points of enzymatic cleavage, though short peptides remain susceptible to peptidase degradation in biological environments. The lyophilized form shows good stability under standard cold storage conditions, making it practical for laboratory use.

Mechanisms of Action Being Investigated

Pancragen is proposed to operate through fundamentally different mechanisms than most research peptides. Rather than binding to cell surface receptors and triggering signal transduction cascades, the working hypothesis positions Pancragen as a peptide that enters cells and interacts directly with nuclear components. Researchers describe this as epigenetic modulation rather than receptor-mediated pharmacology. Several interconnected mechanisms have been identified across cell culture and animal studies.

Epigenetic Gene Regulation Through DNA Interaction

The central proposed mechanism involves Pancragen penetrating cellular membranes and reaching the nucleus, where it interacts with histones and specific DNA sequences in pancreatic cells. Studies have documented alterations in gene promoter methylation patterns for three transcription factors governing pancreatic development: PDX1, PAX6, and NGN3 [1].

DNA methylation at gene promoters typically suppresses gene expression. The hypothesis is that Pancragen alters methylation status at these sites, making the associated genes more accessible for transcription. This represents an epigenetic mechanism because it modifies gene expression without changing the underlying DNA sequence. The tissue-specific nature of the observed effects suggests targeted activity in pancreatic cell types rather than generalized changes across all cell populations.

Transcription Factor Upregulation in Pancreatic Cells

Cell culture studies document Pancragen’s influence on the expression of multiple transcription factors that govern pancreatic development and function. These include PDX1, which regulates pancreatic development broadly; PTF1a and PAX6, which direct acinar and islet cell differentiation; PAX4, FOXA2, and NKX2.2, which support islet of Langerhans maturation; NGN3, which drives endocrine lineage commitment; and NKX6.1, which participates in islet development [2].

Quantified upregulation from published studies includes a 2.7-fold increase in NGN3 expression and 1.6 to 1.8-fold increases in PDX1 and PAX6 expression. These effects were observed specifically in aging cell cultures, where baseline expression of these factors had declined. The finding that Pancragen can elevate expression in aged cells raises research questions about whether declining pancreatic function associated with aging reflects, at least partly, suppressible epigenetic changes rather than irreversible cell loss.

Anti-Apoptotic and Cell Survival Signaling

Laboratory studies show Pancragen modulates multiple proteins associated with cell survival and stress responses. Anti-apoptotic effects include increased expression of MCL-1, an anti-apoptotic protein in the BCL-2 family, alongside decreased expression of p53, a tumor suppressor protein that rises during cellular stress and can trigger programmed cell death [3].

Proliferation markers PCNA and Ki-67 both increase following Pancragen treatment in cell culture models, indicating enhanced cellular replication activity. IGF-1, an insulin-like growth factor with established anti-apoptotic properties, shows modulated levels in treated cultures. The net picture from these markers is a shift toward cell survival and proliferation over stress-induced death, which researchers interpret as consistent with a tissue-regenerative effect.

Aging Biomarker Modulation

Research in aging models documents Pancragen’s effects on markers specifically associated with cellular senescence and age-related dysfunction. Caspase-3 activity decreases following treatment, indicating reduced activation of a key executioner enzyme in the apoptotic cascade. Cathepsin B levels decline, reflecting reduced lysosomal protease activity that otherwise increases in aging tissues. TNF-alpha, a pro-inflammatory cytokine elevated in chronic low-grade inflammation associated with aging, shows modulation toward lower levels [2].

These effects collectively describe a cellular environment shifted away from the pro-inflammatory, pro-apoptotic state characteristic of aging tissue. Researchers interpret this pattern as consistent with geroprotective activity at the cellular level.

Matrix Metalloproteinase Upregulation and Tissue Remodeling

Pancragen treatment increases expression of MMP2 and MMP9, two matrix metalloproteinases involved in extracellular matrix remodeling. These enzymes break down and reorganize structural proteins surrounding cells, a process essential for tissue repair and maintenance of organ architecture. Elevated MMP activity in pancreatic tissue may support structural integrity during the cellular renewal processes the peptide is hypothesized to promote [3].

Glucose-Insulin Regulatory Pathway Modulation

Primate studies document effects on insulin and C-peptide responses to glucose challenge in aged animals. C-peptide, produced in equimolar amounts with insulin during pancreatic beta-cell secretion, serves as a direct marker of endogenous insulin production. Normalization of C-peptide dynamics alongside insulin responses suggests the observed metabolic improvements reflect changes in pancreatic beta-cell function rather than peripheral insulin sensitivity alone [4].

Major Areas of Research

Pancragen research spans several interconnected domains, with glucose metabolism and pancreatic cell biology attracting the most sustained investigation. All research is conducted in preclinical models or limited observational settings.

Glucose Metabolism and Insulin Dynamics Studies

The most extensively documented research area examines Pancragen’s effects on glucose metabolism in aged animal models. Non-human primate studies using aged rhesus monkeys aged 20 to 25 years represent the most advanced preclinical model in this area. These animals show impaired glucose tolerance characteristic of metabolic aging, providing a model closer to human physiology than rodent systems.

Published findings document normalization of glucose clearance rates in aged monkeys following Pancragen treatment, with insulin and C-peptide dynamics shifting toward patterns seen in younger animals. Fasting glucose levels declined during treatment periods. A particularly notable observation is the persistence of these effects for up to three weeks after treatment ended, which researchers interpret as consistent with an epigenetic mechanism rather than a short-acting pharmacological effect [4].

Key Research Highlights:

• Normalized glucose clearance in aged rhesus monkeys (20-25 years)
• Restored insulin and C-peptide dynamics resembling younger animal profiles
• Metabolic effects persisting up to three weeks post-treatment cessation

Pancreatic Cell Differentiation Research

Cell culture studies using human pancreatic cell lines investigate whether Pancragen can influence the differentiation state of pancreatic cells, particularly in aged cultures where marker expression has declined. These studies document increased expression of both acinar and islet cell differentiation factors following Pancragen treatment [2].

The acinar compartment of the pancreas handles digestive enzyme production, while the islet compartment, particularly beta-cells, manages insulin secretion. Both compartments show differentiation marker restoration in treated aged cultures, suggesting the peptide’s proposed epigenetic mechanism may apply broadly to pancreatic cell identity rather than selectively to one cell type.

Key Research Highlights:

• Increased acinar and islet differentiation markers in aged human pancreatic cell cultures
• Upregulation of NGN3 (2.7-fold), PDX1, and PAX6 (1.6-1.8-fold)
• Effects observed in both young and aged culture systems

Diabetic Vascular Complication Research

Streptozotocin-induced diabetes in Wistar rats provides a model for examining Pancragen’s effects on vascular complications of diabetes. Streptozotocin selectively destroys pancreatic beta-cells, creating insulin-deficient diabetes that produces vascular damage resembling human diabetic complications over time.

Studies in this model document normalized adhesion properties of mesenteric capillary endothelial cells in diabetic rats treated with Pancragen. Endothelial dysfunction in diabetes contributes to the vascular complications affecting kidneys, eyes, nerves, and the cardiovascular system. Protection of endothelial function during hyperglycemic conditions may represent a research avenue relevant to diabetic complication prevention, though all findings remain in rodent models [5].

Key Research Highlights:

• Normalized endothelial adhesion properties in streptozotocin-diabetic rats
• Protection of capillary integrity under hyperglycemic conditions
• Potential relevance to diabetic microvascular complication research

Epigenetic Research and Gene Regulation Studies

The proposed nuclear mechanism of Pancragen positions it as a research tool for studying epigenetic regulation of pancreatic gene expression. The documented effects on PDX1, PAX6, and NGN3 promoter methylation patterns provide a framework for investigating how short peptides might modulate chromatin accessibility and transcription factor expression in tissue-specific ways [1].

This area connects Pancragen research to broader questions in epigenetics: whether aging-associated gene silencing is reversible, whether short peptides can serve as targeted epigenetic modulators, and what structural features of a peptide determine its nuclear-penetrating and DNA-interacting properties. These are open research questions with no established answers.

Key Research Highlights:

• Documented methylation changes at PDX1, PAX6, and NGN3 gene promoters
• Possible histone-DNA complex interactions affecting chromatin accessibility
• Effects persisting across cellular passages in culture models

Cellular Aging and Longevity Research

Pancragen’s modulation of aging biomarkers places it within the broader context of geroprotective research. Studies examine whether the peptide can reverse or slow age-associated changes in pancreatic tissue, including the decline in differentiation marker expression, increased apoptosis rates, elevated inflammatory signaling, and reduced regenerative capacity observed in aged pancreatic cells [2,3].

The anti-apoptotic profile documented in cell culture studies, combining reduced caspase-3 and cathepsin B activity with elevated MCL-1 and suppressed p53, describes a cellular environment more resistant to age-associated cell death. Whether these in vitro observations translate to meaningful longevity effects in whole organisms remains an open question.

Key Research Highlights:

• Reduced caspase-3 activity and cathepsin B levels in aging models
• Elevated MCL-1 and suppressed p53 indicating anti-apoptotic signaling shifts
• Proliferation markers PCNA and Ki-67 increased in treated cultures

Comparative Pharmacology: Pancragen Versus Standard Metabolic Agents

Primate studies included a direct comparison between Pancragen and glimepiride, a sulfonylurea drug that stimulates insulin secretion, using aged monkeys with impaired glucose tolerance. Both compounds reduced basal blood glucose. However, their mechanisms diverged in ways that researchers consider significant.

Glimepiride produced more pronounced immediate hypoglycemic effects by stimulating insulin secretion, reflected in elevated C-peptide. Pancragen normalized both insulin and C-peptide levels, which researchers interpret as restoration of coordinated endocrine function rather than forced secretion [6]. This distinction matters because forced oversecretion from exhausted or compromised beta-cells may accelerate beta-cell burnout over time, while functional restoration might preserve long-term capacity. These are hypotheses that require controlled longitudinal study to test.

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Intramuscular injection served as the primary administration route in the primate efficacy studies that generated the most cited metabolic data. This route provides reliable systemic delivery while bypassing gastrointestinal degradation concerns that complicate oral peptide administration.

No dedicated pharmacokinetic studies with rigorous bioavailability measurements across multiple routes have been published for Pancragen. The small molecular size of 576 Da is hypothesized to facilitate cellular membrane crossing, but direct measurements of tissue penetration and nuclear localization in living animals have not been documented in the available literature.

Distribution and Metabolism

Tissue distribution kinetics for Pancragen remain poorly characterized across species. The proposed mechanism involving nuclear penetration requires the peptide to cross both the cell plasma membrane and the nuclear envelope, but direct experimental evidence demonstrating this in vivo is limited. Most mechanistic evidence comes from cell culture systems where nuclear localization is more tractable to study.

Plasma half-life has not been fully characterized. As a short peptide, Pancragen is susceptible to peptidase degradation, and rapid plasma clearance is likely, consistent with most research peptides of comparable length. The observation that metabolic effects persisted for up to three weeks after treatment cessation in primate models is difficult to reconcile with rapid plasma clearance if the mechanism is conventional receptor-mediated pharmacology, which is part of the rationale for the epigenetic mechanism hypothesis.

Delivery Methods Under Investigation

• Intramuscular injection: Primary route used in primate metabolic studies; systemic delivery confirmed through observed biological effects
• Subcutaneous injection: Used in some rodent model studies; standard route for peptide research in small animal models
• Oral administration: Not a primary studied route; susceptibility to gastrointestinal peptidase degradation would limit bioavailability without protective formulation

Excretion and Clearance

Standard peptide degradation pathways involving endopeptidase and exopeptidase activity represent the most likely metabolic route for Pancragen. Breakdown products would consist of individual amino acids or dipeptide fragments entering normal amino acid pools. Renal clearance of small peptide fragments is probable. Detailed excretion studies have not been published.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data The most significant limitation in Pancragen research is the near-complete absence of controlled human clinical trials. Published human data consists of small observational studies in elderly subjects, without randomization, control groups, blinding, or pre-registered endpoints. These studies cannot establish causation, control for confounding variables, or provide reliable safety data. No dose-finding, pharmacokinetic, or formal safety studies have been conducted in humans.

Geographic and Investigator Concentration The vast majority of published Pancragen research originates from a single research group at the St. Petersburg Institute of Bioregulation and Gerontology. Independent replication by separate research teams in different institutions has not been documented in the available literature. Scientific consensus requires independent replication, and this represents a fundamental gap in the Pancragen evidence base.

Mechanistic Characterization The proposed nuclear penetration and direct DNA interaction mechanism lacks direct experimental confirmation in living animal systems. Cell culture evidence supports nuclear effects, but whether the same mechanism operates in vivo, at what concentrations, and in which cell types remains unclear. No specific receptors, binding partners, or structural co-factors have been identified.

Methodological Considerations Animal studies use varying doses, routes, and treatment durations, making cross-study comparisons difficult. The most advanced preclinical model used is aged rhesus monkeys, which provides a stronger translational model than rodents but still differs from human physiology in important ways. Rodent streptozotocin-induced diabetes models have well-documented limitations in predicting human Type 2 diabetes outcomes.

Areas Needing Further Investigation

• Independent replication of published findings by research groups outside the originating institution
• Controlled human clinical trials with pre-registered endpoints, appropriate power, and blinded assessment
• Direct in vivo measurement of tissue distribution and nuclear localization
• Long-term safety studies across multiple species
• Dose-response characterization for all reported effects
• Mechanistic studies identifying specific DNA binding sequences, histone interaction partners, and chromatin accessibility changes

Regulatory and Research Status

Current Classification

FDA Status Pancragen is not approved by the FDA for any human therapeutic application. It carries no Investigational New Drug designation in the public record and has not entered formal FDA regulatory review. As a research chemical, it is available for legitimate laboratory investigation but cannot be marketed or sold for human use. The FDA classifies it as an unapproved new drug substance when used outside research contexts.

WADA Status WADA’s prohibited list categorizes peptide hormones, growth factors, and related substances broadly. Pancragen as a short peptide bioregulator would fall under scrutiny in competitive athletic contexts, though it does not appear as a named substance in publicly available WADA guidance documents. Athletes subject to anti-doping testing should treat any peptide bioregulator with caution.

International Perspective Russia, where the majority of Pancragen research was conducted, has a separate regulatory framework for peptide bioregulators. Several related bioregulator peptides have received approval as dietary supplements or pharmaceutical products in Russia through pathways that differ substantially from FDA or EMA standards. These approvals do not constitute evidence of safety or efficacy by international regulatory standards. EMA has not reviewed or approved Pancragen for any application.

Research Community Approach

Pancragen research sits within the niche field of peptide bioregulator science, which remains outside mainstream pharmaceutical development. Institutional research using Pancragen requires standard laboratory oversight, appropriate biosafety protocols, and compliance with applicable regulations for peptide research chemicals. The compound’s research-use-only status and the concentration of existing research within a specific geographic and institutional context limit broader scientific engagement.

Future Research Directions

Independent replication of the key primate metabolic findings represents the most important near-term research need. If those findings hold under independent scrutiny, formal pharmacokinetic and safety studies in humans would be the logical next step. The epigenetic mechanism hypothesis, if validated with direct experimental evidence, could position Pancragen within the broader context of epigenetic modulator research, an area receiving substantial investment from mainstream pharmaceutical developers working in aging and metabolic disease.

Key Research Findings

Glucose Normalization in Aged Rhesus Monkeys

Research Focus: Effects of Pancragen on glucose tolerance and insulin dynamics in aged non-human primates Key Results: Glucose clearance rates normalized in aged rhesus monkeys showing impaired glucose tolerance; insulin and C-peptide response patterns shifted toward profiles characteristic of younger animals; fasting glucose levels declined; effects persisted for up to three weeks following treatment cessation Significance: Non-human primate models provide the closest available preclinical approximation to human metabolic aging, making these findings the highest-order preclinical evidence in the Pancragen literature Limitations: Single research group; small animal numbers not fully specified in available abstracts; no independent replication [4]

Transcription Factor Restoration in Aged Pancreatic Cell Cultures

Research Focus: Whether Pancragen can restore age-associated decline in pancreatic differentiation marker expression Key Results: NGN3 expression increased 2.7-fold; PDX1 and PAX6 increased 1.6 to 1.8-fold; both acinar and islet cell differentiation markers responded; effects observed in aged cultures where baseline expression had declined Significance: Provides the primary mechanistic evidence for Pancragen’s proposed epigenetic activity in pancreatic cell biology; connects molecular findings to functional outcomes in metabolic studies Limitations: Cell culture systems; human cell lines may not fully replicate in vivo pancreatic biology; single research group [2]

Epigenetic Promoter Methylation Changes

Research Focus: Direct measurement of DNA methylation changes at pancreatic gene promoters following Pancragen exposure Key Results: Methylation pattern alterations documented at PDX1, PAX6, and NGN3 gene promoters; changes correlated with upregulation of corresponding transcription factors; effects described as tissue-specific to pancreatic cell preparations Significance: Provides the most direct available evidence for the proposed epigenetic mechanism; distinguishes Pancragen from receptor-mediated peptides if findings are confirmed Limitations: Mechanistic work conducted primarily in cell culture; in vivo confirmation of promoter methylation changes not documented; requires independent replication [1]

Endothelial Protection in Diabetic Rat Model

Research Focus: Effects on capillary endothelial function in streptozotocin-induced diabetic rats Key Results: Normalized mesenteric capillary endothelial adhesion properties in diabetic animals; maintained capillary integrity under hyperglycemic conditions compared to untreated diabetic controls Significance: Identifies a potential application area in diabetic vascular complication research; suggests Pancragen’s effects extend beyond direct glucose regulation to vascular protection Limitations: Streptozotocin model reflects Type 1 rather than Type 2 diabetes physiology; rodent vascular biology differs from humans; single study [5]

Comparative Study: Pancragen Versus Glimepiride

Research Focus: Direct pharmacological comparison of Pancragen and a standard sulfonylurea drug in aged primates with impaired glucose tolerance Key Results: Both compounds reduced basal blood glucose; glimepiride produced more pronounced hypoglycemia with elevated C-peptide secretion; Pancragen normalized insulin and C-peptide dynamics without driving forced secretion; safety profile assessment favored Pancragen Significance: Suggests a mechanistically distinct metabolic effect profile compared to conventional secretagogue drugs; raises hypothesis that Pancragen restores endocrine function rather than stimulating compromised cells Limitations: Small primate study; favorable safety comparison against glimepiride does not establish human safety; no long-term follow-up data [6]

Anti-Apoptotic Profile in Aging Cell Models

Research Focus: Characterization of Pancragen’s effects on apoptosis-related proteins in aging pancreatic cell culture systems Key Results: Decreased p53 and caspase-3 activity; increased MCL-1 expression; reduced cathepsin B levels; elevated PCNA and Ki-67 proliferation markers; IGF-1 modulation toward anti-apoptotic signaling Significance: Provides a coherent molecular picture of cellular survival promotion that could explain tissue-level regenerative effects observed in animal studies Limitations: In vitro findings; the anti-apoptotic profile requires confirmation in vivo; reduced p53 as a sustained effect raises theoretical considerations about cell cycle regulation that require further study [3]

Frequently Asked Questions

What is Pancragen and what is it made from?

Pancragen is a short synthetic peptide made up of four amino acids: lysine, glutamic acid, aspartic acid, and tryptophan, giving it the shorthand name KEDW. It was originally derived from peptides isolated from bovine pancreatic tissue and then synthesized chemically. Researchers study it as a tetrapeptide bioregulator, meaning a short peptide hypothesized to carry regulatory signals specific to pancreatic tissue biology.

What makes Pancragen different from other research peptides?

Most research peptides work by binding to cell surface receptors and triggering signal cascades from the outside of the cell inward. Pancragen research proposes a different mechanism: the peptide may enter cells and interact directly with DNA and histone proteins inside the nucleus, influencing which genes are active. This proposed epigenetic mechanism is less common among research peptides and is the subject of active investigation.

What research models have been used to study Pancragen?

Pancragen has been studied in aged rhesus monkeys for metabolic and glucose regulation effects, in streptozotocin-induced diabetic rats for vascular effects, in human pancreatic cell cultures for differentiation marker and epigenetic studies, and in small observational studies involving elderly human subjects. The non-human primate studies are considered the most translationally relevant preclinical data, though all findings require independent replication.

How long has Pancragen been studied and who conducts the research?

Pancragen research has been ongoing for more than 20 years, primarily since the early 2000s. The vast majority of published research comes from Professor Vladimir Khavinson’s group at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. This concentration of research within a single institution is itself a recognized limitation, as independent replication by separate research teams has not been documented in the available literature.

Is there human clinical trial data available for Pancragen?

No controlled human clinical trials for Pancragen have been published. The available human data consists of small observational studies conducted in elderly subjects with type 2 diabetes, which lack randomization, blinding, and control groups. These studies cannot establish causation or provide reliable safety profiles. Formal clinical development through registered trials would be required before any conclusions about human efficacy or safety could be drawn.

References

1. Ashapkin, V.V., Khavinson, V.K., Linkova, N.S., & Vanyushin, B.F. (2015). Epigenetic mechanisms of peptide-induced activation of the transcription factor genes PDX1, PAX6, and NGN3 in human pancreatic cell cultures. Biochemistry (Moscow), 80(3), 310-317. PubMed

2. Khavinson, V.K., Linkova, N.S., Kukanova, E.O., Trofimova, S.V., Tendler, S.M., & Kvetnoi, I.M. (2013). Neuroprotective peptide AEDG and tetrapeptide Lys-Glu-Asp-Trp (Pancragen) activate differentiation markers in human pancreatic cell cultures. Bulletin of Experimental Biology and Medicine, 155(4), 466-470. PubMed

3. Khavinson, V.K., Linkova, N.S., Kukanova, E.O., Trofimova, S.V., Tendler, S.M., & Kvetnoi, I.M. (2012). Influence of Lys-Glu-Asp-Trp on functional morphology of human pancreatic cell culture. Bulletin of Experimental Biology and Medicine, 153(5), 764-769. PubMed

4. Goncharova, N.D., Vengerin, A.A., Khavinson, V.K., & Lapin, B.A. (2014). Peptides-induced normalization of age-related dysfunction of glucose-insulin homeostasis in old monkeys. Advances in Gerontology, 27(1), 70-77. PubMed

5. Khavinson, V.K., Razbitnaya, L.A., Trofimova, S.V., & Kvetnoi, I.M. (2007). Immunocytochemical analysis of the effect of pancragen on pancreatic endocrine cells in experimental diabetes mellitus. Bulletin of Experimental Biology and Medicine, 143(5), 620-623. PubMed

6. Goncharova, N.D., Vengerin, A.A., Oganyan, T.E., & Khavinson, V.K. (2015). Comparative effectiveness of peptide bioregulator Pancragen and antidiabetic drug Glimepiride on glucose and insulin homeostasis in old monkeys. Advances in Gerontology, 28(2), 289-295. PubMed

7. Kvetnoi, I.M., Khavinson, V.K., Linkova, N.S., & Trofimova, S.V. (2007). Morphofunctional basis of the geroprotective effects of the pancreatic peptide bioregulator. Bulletin of Experimental Biology and Medicine, 144(4), 571-574. PubMed

8. Korkushko, O.V., Khavinson, V.K., Shatilo, V.B., & Antonyuk-Shcheglova, I.A. (2011). Geroprotective effect of the tetrapeptide Lys-Glu-Asp-Trp (Pancragen) on patients in late accelerated aging. Bulletin of Experimental Biology and Medicine, 150(5), 612-615. PubMed

9. Linkova, N.S., Khavinson, V.K., Kukanova, E.O., Trofimova, S.V., & Kvetnoi, I.M. (2012). Signaling molecules as peptide bioregulator targets in pancreatic aging. Advances in Gerontology, 25(1), 68-76. PubMed

10. Vanyushin, B.F., & Khavinson, V.K. (2014). Short biologically active peptides as epigenetic regulators of gene activity. Results and Problems in Cell Differentiation, 55, 69-89. PubMed

11. Khavinson, V.K., & Morozov, V.G. (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters, 24(3-4), 233-240. PubMed

12. Khavinson, V.K., Linkova, N.S., Trofimova, S.V., & Kvetnoi, I.M. (2010). Peptide regulation of aging and functional activity of pancreatic cells. Advances in Gerontology, 23(4), 527-532. PubMed

13. Ashapkin, V.V., Kutueva, L.I., & Vanyushin, B.F. (2017). Aging as an epigenetic phenomenon. Current Genomics, 18(5), 385-407. PubMed

14. Linkova, N.S., Shataeva, L.K., Khavinson, V.K., & Vanyushin, B.F. (2012). Interaction of short peptides with DNA: Role in regulation of gene expression during aging of the organism. Advances in Gerontology, 25(2), 209-217. PubMed

15. Khavinson, V.K., Tendler, S.M., Kasyanenko, N.A., Tarnovskaya, S.I., Linkova, N.S., Ashapkin, V.V., Shataeva, L.K., & Kvetnoi, I.M. (2015). Tetrapeptide KEDW interacts with DNA and regulates gene expression. American Journal of Biomedical Sciences, 7(1), 17-31. Link

16. Goncharova, N.D., & Lapin, B.A. (2005). Effects of aging on the hypothalamic-pituitary-adrenal axis in non-human primates. Frontiers in Neuroendocrinology, 26(3-4), 132-148. PubMed

17. Feige, J.N., & Auwerx, J. (2012). Transcriptional coregulators in the control of energy homeostasis. Trends in Cell Biology, 17(6), 292-301. PubMed

18. Brissova, M., & Powers, A.C. (2008). Revascularization of transplanted islets: can it be improved? Diabetes, 57(9), 2269-2271. PubMed